Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. Rapid improvement of idiopathic aphthous ulcers with oral roflumilast therapy

    Publikation: Bidrag til tidsskriftLetterpeer review

  2. Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy

    Publikation: Bidrag til tidsskriftLetterpeer review

  1. Assessment of biomarkers in pediatric atopic dermatitis by tape strips and skin biopsies

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Copper release from metals may mask positive nickel spot test results

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Guidelines for diagnosis, prevention, and treatment of hand eczema

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • A. Wollenberg
  • L. A. Beck
  • M. de Bruin Weller
  • E. L. Simpson
  • S. Imafuku
  • M. Boguniewicz
  • R. Zachariae
  • C. K. Olsen
  • J. P. Thyssen
Vis graf over relationer

Background: Tralokinumab, a fully human IgG4 monoclonal antibody that specifically binds with high affinity to interleukin-13, effectively reduces moderate-to-severe atopic dermatitis (AD) when given every 2 weeks. The incidence of conjunctivitis is elevated vs. placebo, but severity and aetiology have not been examined. Objective: To analyse conjunctivitis data recorded in five randomized, placebo-controlled trials of tralokinumab in adult patients with moderate-to-severe AD. Methods: Overall, 2285 adults with AD were studied up to 16 weeks. Cochran–Mantel–Haenszel weights were applied to calculate the adjusted incidence of adverse events. Results: The incidence of conjunctivitis was higher (7·5%) with tralokinumab than with placebo (3·2%). Most events were mild or moderate in severity, and 78·6% and 73·9% of events resolved during the trial in the tralokinumab and placebo groups, respectively. Two (1·4%) events led to the permanent discontinuation of tralokinumab. An increased incidence of conjunctivitis, regardless of treatment group, was associated with more severe baseline AD, and history of allergic conjunctivitis/atopic keratoconjunctivitis, as well as the number of atopic comorbidities. Limitations: This analysis reports events up to week 16 only, with limited confirmation of conjunctivitis and its aetiology by an ophthalmologist, and insufficient reporting of ophthalmic treatments. Conclusions: Treatment with tralokinumab was associated with an increased incidence of conjunctivitis vs. placebo, but these cases were mostly mild and transient.

OriginalsprogEngelsk
TidsskriftBritish Journal of Dermatology
Vol/bind186
Udgave nummer3
Sider (fra-til)453-465
Antal sider13
ISSN0007-0963
DOI
StatusUdgivet - mar. 2022

Bibliografisk note

Publisher Copyright:
© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists

ID: 75487377